Chemical substructures that enrich for biological activity

Area of Science:

• Medicinal Chemistry
• Drug Discovery
• Computational Chemistry

Background:

• Certain chemical substructures are frequently found in drugs, leading to the hypothesis of 'privileged' substructures predisposed to bioactivity.
• The existence of privileged substructures has been debated due to potential biases in screening library construction.

Purpose of the Study:

• To rigorously test and validate the concept of privileged substructures using diverse phenotypic assays.
• To identify novel privileged, underprivileged, and conditionally privileged substructures.
• To explore the mechanistic basis and practical implications of privileged substructures in drug discovery.

Main Methods:

• Utilized diverse phenotypic assays to define bioactivity across multiple compound libraries.
• Statistically analyzed substructure prevalence and association with bioactivity, controlling for library bias.
• Confirmed privileged substructure determinations through independent assays and libraries.

Main Results:

• Validated the privileged substructure concept, identifying numerous substructures associated with bioactivity beyond random chance.
• Discovered 'underprivileged' substructures and 'conditional privilege' rules based on substructure combinations.
• Identified novel three-dimensional privileged substructures, expanding beyond previously known flat aromatic systems.
• Observed that privileged substructures often feature diverse substituents, suggesting an entropic mechanism.
• Compounds with privileged substructures exhibited a doubled rate of bioactivity.

Conclusions:

• The privileged substructure concept is empirically validated, offering a robust framework for drug discovery.
• The identification of diverse privileged substructures, including 3D and conditionally privileged ones, provides new avenues for rational drug design.
• Privileged substructures significantly enhance bioactivity rates, demonstrating practical utility and potential to accelerate pharmaceutical development.